JabWatch journal

UK first in Europe to authorise orforglipron for weight management and type 2 diabetes

Source published 10 August 2026 · JabWatch published 13 August 2026 · Last updated 23 August 2026

The UK has become the first European country to authorise orforglipron for weight management and the treatment of type 2 diabetes, according to the MHRA. The announcement concerns regulatory approval and does not confirm NHS funding or launch pricing.

Original source

This JabWatch summary links to the original report: GOV.UK / MHRA.

Context

JabWatch provides consumer price information, not medical advice. Check the original source and a pharmacy's terms for the latest details.